植入型心律转复除颤器一级预防的卫生经济学研究进展

Advance in Economic Analysis for ICD Primary Prevention

简要介绍植入型心律转复除颤器一级预防的临床试验及相关的卫生经济学分析。植入型心律转复除颤器一级预防的卫生经济学分析影响因素众多,结果差异也较大,增量成本-效果比从$8 539至44 736。应加强心脏性猝死高危患者的识别,关注器械的技术进步。在中国宜开展相应的卫生经济学研究,为合理分配有限的医疗资源提供数据。

This review briefly introduces the clinical trials of primary prevention about implantable cardioverter defibrillator（ICD） and relevant economic analyses. Due to varied influencing factors of ICD primary prevention economic analysis, the incremental cost-effectiveness ratio（ICER） ranged from $8,539 to €44,736. It is important to focus on identifying the high risk patients and pay attention to device technological improvement. Related economic analysis of ICD primary prevention should be conducted in China to provide data for beter distribution of limited health care resources.